The Rise of ADC’s in Gynecologic Cancer: Transitioning from Research to Practice

Resort at Squaw Creek
Olympic Valley, California
Friday, January 28, 2022

OUR PROGRAM WILL BEGIN SOON

A GOG Foundation, Inc. Educational Program
The Rise of ADC’s in Gynecologic Cancer: Transitioning from Research to Practice

Resort at Squaw Creek
Olympic Valley, California
Friday, January 28, 2022

A GOG Foundation, Inc. Educational Program
LEARNING OBJECTIVES

The overall objective of this symposia is to increase clinicians’ knowledge and competence regarding the various targeted antibody drug conjugates available. learners will also understand how to best incorporate these advanced treatments into clinical practice.

Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding

- Understanding targeted drug therapy as a treatment option for patients with ovarian and cervical cancer;
- Increased knowledge regarding advanced treatments available for ovarian and cervical cancer;
- Identify adverse events and understand management to facilitate therapy;
- Learn how to best implement treatment into practice to improve patient outcomes.
GOG FACULTY DISCLOSURE INFORMATION

Symposium, “The Rise of ADC’s in Gynecologic Cancer: Transitioning from Research to Practice”

JANUARY 28, 2022
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role(s) in Activity</th>
<th>Nothing To Disclose</th>
<th>Disclosure (Company &amp; Role)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramez Eskander, MD</td>
<td>Planning/Speaker</td>
<td></td>
<td>Advisory Board/Consulting Fee/Speaking: AstraZeneca, Merck, Clovis, GSK, Myriad</td>
</tr>
<tr>
<td>Thomas Herzog, MD</td>
<td>Planning/Speaker</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Kathleen Moore, MD</td>
<td>Speaker</td>
<td></td>
<td>Advisory board: AstraZeneca, Aravive, Blueprint, Alkemeres, OmgXema, Eisai, GSK, Elevar, Genentech, Immunogen, Merck, VBL, Mersana, Myriad</td>
</tr>
<tr>
<td>David O’Malley, MD</td>
<td>Speaker</td>
<td></td>
<td>Honorarium: Roche Diagnostics, Watermark, Immunogen, AstraZeneca, Sorrento, Rubius, Elevar, Novartis, Eisai, GSK, Novocure, Genentech, GOG Foundation, Mersana, Seattle Genetics, Ambry, Regeneron, Myriad, GSK/Tesaro, Agenus</td>
</tr>
<tr>
<td>Bhavana Pothuri, MD</td>
<td>Speaker</td>
<td></td>
<td>Research funding support / Ad Board fees: AstraZeneca, Celsion, Immunogen, Merck, Mersana, Seattle Genetics, Sutro, Takada, Tesaro, Clovis Oncology Advisory Board: Eisai, Lilly, GOG Foundation</td>
</tr>
<tr>
<td>Leslie Randall, MD</td>
<td>Speaker</td>
<td></td>
<td>Consulting Fee: Agenus, Clovis, Myriad, Mersana, GSK/Tesaro Research Grant/Contractor: Merck, Pfizer</td>
</tr>
<tr>
<td>Michelle Small</td>
<td>Staff</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Jill Reese</td>
<td>Staff</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMAPRA Category 1 Credits™
The GOG Foundation, Inc. designates this internet live activity for a maximum of 1.50 AMAPRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
COMMERCIAL SUPPORTERS

The GOG Foundation, Inc. and GOG Partners would like to thank our commercial supporters for their unrestricted educational grants associated with this Symposium: *ImmunoGen, Mersana, Genmab and Seagen Inc.*
FACULTY

Ramez Eskander, MD, UC San Diego, Moores Comprehensive Cancer Center, San Diego, California, USA

Thomas J. Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA

Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA

David O’Malley, MD, The Ohio State University, James Cancer Center, Columbus, Ohio, USA

Bhavana Pothuri, MD, NYU Langone, New York City, New York, USA

Leslie Randall, MD, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
THANK YOU

View this symposium on-demand at GOG.org or the GOG YouTube channel